Goldman Sachs Group Inc. Has $3.45 Million Stock Position in Establishment Labs Holdings Inc. $ESTA

Key Points

• Goldman Sachs Group Inc. decreased its stake in Establishment Labs Holdings Inc. by 39.6%, selling 55,382 shares and retaining 84,468 shares worth approximately $3.45 million as of the latest SEC filing.
• Establishment Labs reported a quarterly loss of $0.57 per share, falling short of analysts' expectations, but its revenue increased 16.1% year-over-year, reaching $51.30 million.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Establishment Labs, with an average price target of $56.50, indicating a positive outlook despite a recent downgrade from Needham & Company LLC.

Goldman Sachs Group Inc. decreased its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 39.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,468 shares of the company's stock after selling 55,382 shares during the quarter. Goldman Sachs Group Inc. owned about 0.29% of Establishment Labs worth $3,447,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in ESTA. Elevation Point Wealth Partners LLC purchased a new stake in Establishment Labs in the 1st quarter worth approximately $207,000. Mudita Advisors LLP boosted its stake in shares of Establishment Labs by 15.6% in the 1st quarter. Mudita Advisors LLP now owns 479,359 shares of the company's stock worth $19,560,000 after buying an additional 64,859 shares during the last quarter. New York State Common Retirement Fund purchased a new position in Establishment Labs during the first quarter valued at $894,000. Swiss National Bank raised its holdings in Establishment Labs by 1.3% during the first quarter. Swiss National Bank now owns 39,000 shares of the company's stock valued at $1,591,000 after acquiring an additional 500 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Establishment Labs by 53.9% in the fourth quarter. Northern Trust Corp now owns 28,165 shares of the company's stock worth $1,298,000 after buying an additional 9,865 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company's stock.

Establishment Labs Trading Down 2.7%

Shares of NASDAQ ESTA traded down $1.09 during trading on Friday, hitting $39.46. 158,628 shares of the company traded hands, compared to its average volume of 236,551. Establishment Labs Holdings Inc. has a 1 year low of $26.56 and a 1 year high of $50.85. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. The firm has a market capitalization of $1.14 billion, a P/E ratio of -12.94 and a beta of 0.85. The company has a 50-day moving average price of $40.24 and a 200-day moving average price of $37.90.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). The firm had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The business's quarterly revenue was up 16.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.62) EPS. Establishment Labs has set its FY 2025 guidance at EPS. On average, equities analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ESTA. Wall Street Zen lowered Establishment Labs from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Needham & Company LLC restated a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a research report on Friday, June 13th. Canaccord Genuity Group initiated coverage on Establishment Labs in a report on Wednesday, August 20th. They issued a "buy" rating and a $60.00 price objective on the stock. Mizuho lifted their target price on shares of Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Finally, Citigroup boosted their target price on shares of Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.50.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.